Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir

AIDS. 2020 Nov 15;34(14):2137-2139. doi: 10.1097/QAD.0000000000002634.

Authors

Hugo Soudeyns^{1

2

3}, Julie Dumond⁴

Affiliations

¹ Unité d'immunopathologie virale, Centre de recherche du CHU Sainte-Justine.
² Départment of Microbiology, Infectiology & Immunology.
³ Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
⁴ Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

PMID: 33105171
DOI: 10.1097/QAD.0000000000002634

No abstract available

Publication types

Comment

MeSH terms

Amides
Female
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring
Heterocyclic Compounds, 4 or More Rings
Humans
Integrase Inhibitors* / pharmacokinetics
Integrases
Piperazines
Placenta* / metabolism
Pregnancy
Pyridones

Substances

bictegravir
cabotegravir